1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Alaska Air Group reported second-quarter 2025 results on July 23, 2025. Total operating revenue rose 28% to $3.7 billion, but GAAP net income fell to $172 million from $220 million a year earlier, and adjusted EPS fell to $1.78 from $2.55, though the 2025 figure exceeded the company's prior adjusted EPS guidance range of $1.15 to $1.65. The 2025 quarter includes Hawaiian Airlines, while the 2024 comparison does not, and management expects full-year EPS greater than $3.25 and third-quarter adjusted EPS of $1.00 to $1.40.
Q2 GAAP net income was $172 million, or $1.42 per share, versus $220 million, or $1.71 per share, in Q2 2024
Q2 adjusted EPS was $1.78, above the prior guidance range of $1.15 to $1.65; the 2024 comparison was $2.55
Third-quarter adjusted EPS is expected at $1.00 to $1.40, including an expected 10 cent impact from a July IT outage; full-year EPS is expected to be greater than $3.25
Repurchased 8.7 million shares for about $428 million in Q2; the company reported $2.1 billion in unrestricted cash and marketable securities as of June 30, 2025
Banc of California reported second quarter 2025 GAAP earnings of $0.12 per diluted share, down from $0.26 in the first quarter, with net earnings available to common stockholders of $18.4 million. Management said adjusted EPS was $0.31, but the GAAP decline reflects a $39.1 million credit loss provision tied partly to $506.7 million of loans moved to held for sale and a $9.8 million one-time tax charge, which matter to shareholders' reported profit.
GAAP diluted EPS was $0.12 versus $0.26 in Q1 2025; adjusted EPS was $0.31
Total revenue rose 3% to $272.8 million; the provision for credit losses was $39.1 million versus $9.3 million in Q1
$506.7 million of loans were transferred to held for sale, with $441.2 million carrying value after the transfer
The company repurchased $111.5 million of common stock in the second quarter and had $150.0 million left under its authorization as of June 30, 2025
United Rentals reported second-quarter 2025 revenue of $3.943 billion, up from $3.773 billion a year earlier, while net income fell 2.2% to $622 million. The company raised its 2025 total revenue outlook to $15.8 billion to $16.1 billion and increased its planned 2025 share repurchases by $400 million to $1.9 billion, which matters to shareholders because it signals higher expected cash returns alongside weaker profit.
Q2 2025 total revenue was $3.943 billion versus $3.773 billion in Q2 2024; net income was $622 million versus $636 million.
GAAP diluted EPS was $9.59 versus $9.54 a year earlier; adjusted EPS was $10.47.
2025 total revenue outlook raised to $15.8 billion to $16.1 billion from $15.6 billion to $16.1 billion.
Board raised the repurchase program from $1.5 billion to $2.0 billion; $1.65 billion is planned for 2025 and $350 million carries into 2026.
RenaissanceRe reported second-quarter 2025 results on July 23, 2025. Net income available to common shareholders rose to $826.5 million, or $17.20 per diluted share, from $495.0 million a year earlier, while operating income available to common shareholders fell to $594.6 million, or $12.29 per diluted share, from $650.8 million, or $12.41 per diluted share.
Net income available to common shareholders: $826.5 million, or $17.20 per diluted share, versus $495.0 million, or $9.41, in Q2 2024
Operating income available to common shareholders: $594.6 million, or $12.29 per diluted share, versus $650.8 million, or $12.41, in Q2 2024
Combined ratio improved to 75.1% from 81.1%; net realized and unrealized investment gains were $349.7 million
Repurchased about 1.6 million common shares for $376.4 million in Q2 and a further 293.8 thousand shares for $70.2 million from July 1 to July 21, 2025
WEX reported second-quarter 2025 results on July 23, 2025. Total revenue fell 2% to $659.6 million, while GAAP net income declined to $68.1 million from $77.0 million, though GAAP diluted EPS rose to $1.98 from $1.83 on a smaller share count. The company also updated full-year 2025 guidance, now expecting revenue of $2.61 billion to $2.65 billion and adjusted EPS of $15.37 to $15.77, for shareholders weighing the company's revenue trend against its per-share profit measures.
Q2 2025 revenue was $659.6 million, down from $673.5 million, including a $15.9 million unfavorable impact from fuel prices and spreads
Q2 adjusted net income was $136.2 million, or $3.95 per diluted share, up from $3.91 a year earlier; GAAP operating income margin was 23.8% versus 25.0%
Third-quarter 2025 guidance: revenue of $669 million to $689 million and adjusted EPS of $4.30 to $4.50
Full-year 2025 guidance: revenue of $2.61 billion to $2.65 billion and adjusted EPS of $15.37 to $15.77; the filing does not state the prior guidance figures
Waystar signed a merger agreement to acquire Iodine Software, a clinical intelligence software company, for an enterprise value of $1.25 billion, consisting of about $625 million in cash and Waystar common stock. The company also reported preliminary second quarter 2025 revenue of approximately $271 million, up about 15% year over year, and said the deal will bring Iodine's equity holders about 8% of the combined company. Closing is subject to customary conditions and regulatory approvals, with a termination date of November 23, 2025.
Enterprise value of $1.25 billion, including about $625 million in cash consideration plus Waystar shares issued to Iodine's Parent equityholders
Current Waystar shareholders expected to own about 92% of the combined company; Iodine equity holders about 8%
Estimated adjusted net leverage ratio at closing of about 3.5x; closing expected by year-end 2025
Preliminary Q2 2025 revenue of about $271 million, about 15% year-over-year growth; full results due July 30, 2025
Interparfums reported second-quarter 2025 net sales of $334 million, down 2% from $342 million a year earlier, while net sales for the six months ended June 30, 2025 rose 1% to $673 million. European based sales rose 6% in the quarter, but United States based sales fell 20%, which management attributed mainly to the discontinuation of the Dunhill license; full financial results are due August 5, 2025.
Q2 2025 net sales: $334 million, down 2% from $342 million in Q2 2024
Six months ended June 30, 2025 net sales: $673 million, up 1% from $666 million
European based net sales rose 6% to $241 million; United States based net sales fell 20% to $96 million
Full results for the three and six months ended June 30, 2025 to be released August 5, 2025; conference call August 6, 2025 at 11:00 am ET
Getty Realty reported second quarter 2025 results, with revenues from rental properties rising to $52.7 million from $48.7 million a year earlier. Net earnings per share fell to $0.24 from $0.30, while AFFO per share rose to $0.59 from $0.58. The company raised its 2025 AFFO per share guidance to $2.40 to $2.41 from $2.38 to $2.41, citing year-to-date investment activity and the resolution of a previously disclosed tenant bankruptcy.
Revenues from rental properties were $52.7 million for the quarter ended June 30, 2025, up from $48.7 million in the same period of 2024.
Net earnings per diluted share were $0.24, down from $0.30; FFO per share was $0.49, down from $0.55.
AFFO per share was $0.59, up from $0.58, and the 2025 AFFO guidance range was raised to $2.40 to $2.41 per diluted share.
ARMOUR Residential REIT reported an unaudited second-quarter 2025 GAAP net loss to common stockholders of $78.6 million, or $0.94 per share, compared with net income of $24.3 million in the first quarter. The company's table of drivers shows losses on interest rate swaps and futures contracts, and its book value per common share fell to $16.90 from $18.59. Distributable Earnings available to common stockholders were $64.9 million, or $0.77 per share, down from $0.86 per share in Q1, while the company continued its $0.24 monthly common dividend.
GAAP net loss to common stockholders of $78.6 million, or $0.94 per share, versus net income of $24.3 million, or $0.32 per share, in Q1 2025
Distributable Earnings available to common stockholders of $64.9 million, or $0.77 per share, versus $0.86 per share in Q1 2025
Book value per common share of $16.90 at June 30, 2025, compared with $18.59 at March 31, 2025; total economic return was (5.22)% for Q2
Common dividend of $0.24 per share payable July 30, 2025, with another $0.24 declared for payment August 29, 2025
Sonoco reported second quarter 2025 net sales of $1.9 billion, up 49.4%, mainly from the December 2024 Eviosys acquisition. GAAP net income attributable to Sonoco rose to $493 million, largely from the April 2025 sale of its Thermoformed and Flexibles Packaging business, while adjusted diluted EPS was $1.37, up 7%. The company now targets full-year adjusted EPS of about $6.00, the low end of its previous $6.00 to $6.20 range, and about $800 million of operating cash flow, the low end of its previous $800 million to $900 million range.
Q2 net sales were $1.9 billion, up 49.4% from the prior-year quarter; Consumer Packaging net sales rose 110% to $1.2 billion.
GAAP net income attributable to Sonoco was $493 million, or $4.96 per diluted share, versus $91 million in Q2 2024; the company said $425 million of the increase, net of tax, came from the TFP sale.
Adjusted EPS was $1.37, up 7% from $1.28; adjusted EBITDA was $328 million, up 25%.
Full-year 2025 adjusted EBITDA guidance of $1.3 billion to $1.4 billion was maintained; operating cash flow was $(15) million for the first six months of 2025.
Selective Insurance Group reported second-quarter 2025 net income available to common stockholders of $83.6 million, or $1.36 per diluted share, compared with a loss of $65.6 million, or $1.08 per share, a year earlier. The GAAP combined ratio improved to 100.2% from 116.1%, but the company raised its 2025 combined ratio guidance to 97% to 98% from 96% to 97%, a higher ratio that means weaker underwriting profitability, while raising its after-tax net investment income guidance to $415 million from $405 million.
Net premiums written rose 5% to $1,288.6 million in the second quarter.
The combined ratio was 100.2%, including $45 million, or 3.8 points, of unfavorable prior year casualty reserve development.
Book value per common share was $52.09, up 3% from the prior quarter, and the company repurchased no shares in the second quarter.
The Board declared a quarterly common dividend of $0.38 per share, payable September 2, 2025, to holders of record on August 15, 2025.
Crown Castle reported second-quarter 2025 results and raised its full-year 2025 outlook, with net income and diluted earnings per share up from a year earlier. Site rental revenues, Adjusted EBITDA and AFFO declined, and the company is selling its fiber and small cells businesses for $8.5 billion, with closing expected in the first half of 2026. Results exclude the Fiber Business, which is presented as discontinued operations.
Q2 2025 site rental revenues were $1,008 million, down 5% from $1,064 million in Q2 2024.
Q2 2025 net income was $291 million, or $0.67 per diluted share, versus $251 million, or $0.58, a year earlier.
Q2 2025 Adjusted EBITDA was $705 million, down 3% from $727 million; AFFO was $444 million, or $1.02 per share.
Full-year 2025 AFFO outlook midpoint rose $35 million to $1,830 million; Adjusted EBITDA midpoint rose $25 million to $2,805 million.
Molina Healthcare reported second quarter 2025 GAAP earnings of $4.75 per diluted share, down 8% from a year earlier, and adjusted earnings of $5.48, down 6%, while premium revenue rose 15% to about $10.9 billion. The company revised its full-year 2025 guidance, now expecting adjusted earnings of no less than $19.00 per share, with premium revenue guidance reaffirmed at about $42 billion, and management attributed the pressure to medical cost trends.
Q2 2025 GAAP EPS $4.75 vs. $5.17 in Q2 2024; adjusted EPS $5.48 vs. $5.86
Premium revenue about $10.9 billion, up 15%; consolidated medical care ratio 90.4% vs. 88.6%
Full-year 2025 guidance: GAAP EPS no less than $16.90; adjusted EPS no less than $19.00
Parent company cash and investments about $100 million at June 30, 2025, vs. $445 million at December 31, 2024
Raymond James reported fiscal third-quarter 2025 net revenues of $3.40 billion, up 5% from a year earlier, while net income available to common shareholders fell 11% to $435 million, or $2.12 per diluted share. The decline reflected a $58 million reserve tied to settling a legal matter over bond underwritings for a specific issuer, which the firm said it resolved without admitting wrongdoing. For shareholders, revenue growth was offset by lower profit and earnings per share.
Quarterly net revenues of $3.40 billion, up 5% year over year and flat compared with the prior quarter
Net income available to common shareholders of $435 million, down 11% year over year; diluted EPS of $2.12 versus $2.31 a year earlier
$58 million reserve increase tied to settling a legal matter over bonds sold to institutional investors between 2013 and 2015; the firm denied liability
Repurchased $451 million of common stock in the quarter; $749 million remained under the buyback authorization as of June 30, 2025
Annaly Capital Management reported second-quarter 2025 results on July 23, 2025. GAAP net income fell to $0.03 per average common share from $0.15 in the first quarter, while earnings available for distribution rose slightly to $0.73 per share, and the $0.70 quarterly dividend was unchanged. Book value per common share declined to $18.45 from $19.02, and GAAP leverage rose to 7.1x from 6.8x.
GAAP net income of $0.03 per average common share, down from $0.15 in Q1 2025 and a loss of $(0.09) in Q2 2024.
Earnings available for distribution (EAD) of $0.73 per average common share, up from $0.72 in Q1 2025.
Book value per common share of $18.45 at June 30, 2025, down from $19.02 at March 31, 2025.
Common stock cash dividend of $0.70 per share for the second quarter; raised $761 million through its at-the-market sales program.
EastGroup Properties reported second-quarter 2025 results on July 23, 2025, with diluted EPS of $1.20 versus $1.14 a year earlier and FFO excluding gains on involuntary conversion and business interruption claims of $2.21 per share, up 7.8%. The company narrowed its 2025 FFO per share outlook to $8.89 to $9.03 from $8.84 to $9.04 in April, while average occupancy of the operating portfolio fell to 95.9% from 97.0%. For shareholders, the per-share earnings and FFO measures improved, although occupancy declined.
Diluted EPS was $1.20 for Q2 2025 versus $1.14 for Q2 2024; FFO excluding certain gains was $2.21 versus $2.05, an increase of 7.8%.
Same PNOI excluding lease terminations rose 6.6% on a straight-line basis for Q2 2025; rental rates on new and renewal leases rose an average of 44.4%.
Average occupancy of the operating portfolio was 95.9% in Q2 2025 versus 97.0% in Q2 2024; the portfolio was 96.0% occupied at June 30, 2025.
2025 guidance: FFO per share of $8.89 to $9.03 (April range $8.84 to $9.04) and EPS of $4.76 to $4.90.
Chipotle reported second quarter 2025 results for the period ended June 30, 2025, with total revenue up 3.0% to $3.1 billion while comparable restaurant sales fell 4.0% and diluted EPS declined to $0.32 from $0.33. The company also disclosed that its Board authorized an additional $400 million in share repurchases, on top of previously announced programs, which matters to shareholders because it adds to capital returned while profit per share and margins declined.
Total revenue rose 3.0% to $3.1 billion, driven by new restaurant openings; comparable restaurant sales decreased 4.0%, with transactions down 4.9%.
Operating margin was 18.2%, down from 19.7%; restaurant level operating margin was 27.4%, down from 28.9%.
Net income was $436.1 million, or $0.32 per diluted share, versus $455.7 million, or $0.33, a year earlier.
The Board's $400 million repurchase authorization was approved June 10, 2025; $838.8 million remained available as of June 30, 2025, and the program may be modified, suspended or discontinued at any time.
Reliance, Inc. reported second-quarter 2025 net sales of $3.66 billion, up 5.0% from the first quarter but up only 0.5% from a year earlier. Diluted EPS was $4.42, up 18.2% from the first quarter but down 5.4% from the second quarter of 2024. The company expects non-GAAP EPS of $3.60 to $3.80 for the third quarter, which is below its second-quarter non-GAAP EPS of $4.43.
Q2 2025 net sales were $3.66 billion, up 5.0% from Q1 2025 and up 0.5% from Q2 2024.
Diluted EPS was $4.42 versus $3.74 in Q1 2025 and $4.67 in Q2 2024; non-GAAP diluted EPS was $4.43.
Q3 2025 non-GAAP EPS is expected at $3.60 to $3.80, including $0.36 per share of LIFO expense; tons sold are expected to fall 1.0% to 3.0% from Q2.
Reliance repurchased $79.9 million of common stock in Q2 and declared a $1.20 per share quarterly dividend on July 22, 2025, payable August 29, 2025.
Goosehead Insurance reported second quarter 2025 results on July 23, 2025. Total revenue rose 20% to $94.0 million and Adjusted EBITDA rose to $29.2 million, but net income fell to $8.3 million from $10.9 million, and basic EPS fell to $0.20 from $0.25, partly due to a $4.7 million impairment charge tied to three office leases. The company kept its full-year 2025 revenue outlook of $350 million to $385 million.
Total revenues were $94.0 million, up 20% from $78.1 million a year earlier; Core Revenue was $86.8 million, up 18%.
Net income was $8.3 million versus $10.9 million; basic EPS was $0.20 versus $0.25.
Adjusted EBITDA was $29.2 million versus $24.7 million, while the Adjusted EBITDA margin was 31% versus 32%.
2025 guidance: total revenues of $350 million to $385 million and total written premiums of $4.38 billion to $4.65 billion.
M/I Homes reported second-quarter 2025 results on July 23, 2025. Revenue rose 5% to $1.2 billion and homes delivered rose 6% to 2,348, but pre-tax income fell 18% to $160 million and diluted EPS fell to $4.42 from $5.12. New contracts fell 8%, which may affect future deliveries.
Net income was $121 million ($4.42 per diluted share) versus $147 million ($5.12) a year earlier.
Pre-tax income decreased 18% to $160 million, or 14% of revenue.
New contracts fell 8% to 2,078 homes; backlog units fell 25% to 2,577 as of June 30, 2025.
The company repurchased $50 million of common stock in the quarter.
Lamb Weston reported fiscal fourth-quarter 2025 net sales up 4% to $1,675.8 million, while net income fell 7% to $119.9 million and diluted EPS fell to $0.85. For fiscal 2026 it guided to net sales of $6.35 billion to $6.55 billion and Adjusted EBITDA of $1,000 million to $1,200 million, compared with fiscal 2025 Adjusted EBITDA of $1,220.5 million, and announced a Focus to Win plan with at least $250 million of savings.
Q4 2025 net sales were $1,675.8 million, up 4%, with volume up 8% and price/mix down 4%.
Q4 2025 net income was $119.9 million, down 7%; Adjusted Diluted EPS was $0.87, up 12%.
Fiscal 2026 outlook: net sales of $6.35 billion to $6.55 billion and Adjusted EBITDA of $1,000 million to $1,200 million, including a 53rd week.
Focus to Win plan targets at least $250 million of savings by the end of fiscal 2028, with about $200 million by fiscal 2027 end.
Healthcare Services Group reported second-quarter revenue of $458.5 million, up 7.6% from a year earlier, but posted a net loss of $32.4 million, or $0.44 per diluted share, compared with a net loss of $1.8 million a year earlier. The loss includes a $0.65 per share non-cash charge tied to the previously announced Genesis HealthCare restructuring. The company raised its 2025 cash flow from operations forecast, excluding the change in payroll accrual, and announced a $50.0 million share repurchase plan over the next 12 months.
Revenue of $458.5 million for the three months ended June 30, 2025, up 7.6% over the prior year
Net loss of $32.4 million, or $0.44 per diluted share, including a $0.65 per share non-cash Genesis restructuring charge ($61.2 million pretax)
2025 cash flow from operations forecast, excluding payroll accrual changes, raised to $70.0 to $85.0 million from $60.0 to $75.0 million
Board-authorized plan to repurchase $50.0 million of common stock over 12 months; $7.6 million repurchased in the second quarter
ANI Pharmaceuticals said it expects combined ILUVIEN and YUTIQ net revenues of $22.3 million for the quarter ended June 30, 2025. The figures are preliminary and unaudited, and the filing gives no prior-year comparison. The company also reported that the primary endpoint of its NEW DAY trial of ILUVIEN for diabetic macular edema was not met, though a secondary endpoint was met.
Preliminary, unaudited combined ILUVIEN and YUTIQ net revenues of $22.3 million for the three months ended June 30, 2025; results not yet reviewed by auditor EisnerAmper LLP
NEW DAY primary endpoint not met: 2.4 vs. 2.5 mean supplemental aflibercept injections (p=0.756)
Secondary endpoint met: mean time to first supplemental aflibercept injection of 185.4 days for ILUVIEN vs. 132.8 days for aflibercept (p<0.001)
Post-hoc analysis in a subset without major protocol deviations showed 1.8 vs. 2.5 injections (p=0.029); results presented July 23, 2025 at the ASRS meeting with a conference call at 8:30 am ET
Hasbro reported second-quarter 2025 revenue of $980.8 million, down 1% from a year earlier, and a net loss attributable to Hasbro of $855.8 million, or $6.10 per share, driven by a $1,021.9 million non-cash goodwill impairment in its Consumer Products segment that the company tied to tariffs. Adjusted net earnings were $1.30 per diluted share, up $0.08, and the company raised its full-year adjusted EBITDA guidance to $1.17 billion to $1.20 billion from $1.1 billion to $1.15 billion. The large charge sharply reduced shareholders' equity, which stood at $269.7 million at June 29, 2025.
Q2 revenue was $980.8 million, down 1%; MAGIC: THE GATHERING revenue rose 23% to $412.0 million.
Net loss was $855.8 million, or $6.10 per share, including a $1,021.9 million goodwill impairment.
Adjusted net earnings were $1.30 per diluted share, an $0.08 improvement year over year.
Full-year adjusted EBITDA guidance was raised to $1.17 billion to $1.20 billion; a $0.70 quarterly dividend is payable September 3, 2025.
Otis reported second quarter 2025 net sales of $3.6 billion, flat from a year earlier, with GAAP EPS down 3% to $0.99 and adjusted EPS down 1% to $1.05. Service net sales rose 6% while New Equipment net sales fell 10%, and the company's full-year 2025 ranges call for adjusted EPS of $4.00 to $4.10, up 4% to 7%. Shareholders see mixed signals: current-quarter profit declined, but the updated full-year ranges point to higher earnings.
Second quarter net sales were $3,595 million versus $3,601 million a year earlier, flat year over year.
GAAP EPS was $0.99 versus $1.02 (down 3%); adjusted EPS was $1.05 versus $1.06 (down 1%).
New Equipment net sales fell 10% to $1.3 billion, with China orders down more than 20%; Service net sales rose 6% to $2.3 billion.
Full-year 2025 outlook: net sales of $14.5 to $14.6 billion and adjusted EPS of $4.00 to $4.10.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.